The Personalized Acne Treatment Tool - Recommendations to facilitate a patient-centered approach to acne management from the Personalizing Acne: Consensus of Experts.

Background: Acne, a commonly treated skin disease, requires patient-centered management due to its varying presentations, chronicity, and impact on health-related quality of life. Despite this, evidence-based clinical guidelines focus primarily on clinical severity of facial acne, omitting important patient- and disease-related factors, including ongoing management.
Objectives: To generate recommendations to support patient-centered acne management, which incorporate priority and prognostic factors beyond conventional clinical severity, traditionally defined by grading the appearance and extent of visible lesions.
Methods: The Personalizing Acne: Consensus of Experts consisted of 17 dermatologists who used a modified Delphi approach to reach consensus on statements regarding patient- and treatment-related factors pertaining to patient-centered acne management. Consensus was defined as ≥75% voting "agree" or "strongly agree."
Results: Recommendations based on factors such as acne sequelae, location of acne, high burden of disease, and individual patient features were generated and incorporated into the Personalized Acne Treatment Tool.
Limitations: Recommendations are based on expert opinion, which may differ from patients' perspectives. Regional variations in healthcare systems may not be represented.
Conclusions: The Personalizing Acne: Consensus of Experts panel provided practical recommendations to facilitate individualized management of acne, based on patient features, which can be implemented to improve treatment outcomes, adherence, and patient satisfaction.
Competing Interests: All panel members received honoraria from Galderma for participating in this project. Alison M Layton has acted as an advisor or consultant, been chief investigator for research (funded to institution) and/or received honoraria for unrestricted educational events from Almirall, Beiersdorf, Cipher Pharmaceuticals, Galderma, GlaxoSmithKline, La Roche-Posay, LEO Pharma, L’Oreal, Mylan, Origimm, and Proctor and Gamble. Andrew Alexis has received grant/research support (funds to institution) from Abbvie, Almirall, Amgen, Arcutis, Bausch Health, Bristol-Myers Squibb, Cara, Castle, Dermavant, Galderma, LEO Pharma, Novartis, Vyne, acted as a consultant/advisory board attendee for Abbvie, Allergan, Almirall, Amgen, Arcutis, Bausch Health, Beiersdorf, BMS, Cara, Cutera, Dermavant, Eli Lilly, EPI, Galderma, Janssen, LEO Pharma, L’Oreal, Ortho, Pfizer, Sanofi-Regeneron, Sol-Gel, Swiss American, UCB, VisualDx, Vyne. Hilary Baldwin has acted as an investigator, consultant, and/or speaker for Almirall, Bausch Health, Cassiopea, EPI Health, Galderma, La Roche-Posay, L’Oreal, Mayne Pharma, Sol-Gel, Sun Pharma, and Vyne. Vincenzo Bettoli has acted as a consultant, advisory board member, research investigator and received honoraria from AbbVie, Beiersdorf, Bioderma, Biogena, Difa-Cooper, Galderma, Ganassini, GlaxoSmithKline, ICF, LEO Pharma, L’Oreal, Meda, Menarini-Relife, Mylan, Novartis, Pharcos-Biodue, UCB Pharma, and received research support (funds to institution) from AbbVie. James Del Rosso has acted as a research investigator, consultant and/or speaker for Almirall, Bausch Health (Ortho Dermatology), BiopharmX, EPI Health, Galderma, LEO Pharma, Mayne Pharma, Sol-Gel, Sonoma, Sun Pharma, and Vyne Therapeutics (Foamix). Thomas Dirschka has received grants/research support from Almirall, Biofrontera, Galderma, Meda, Schulze & BöhmGmbH, has lectured for Almirall, Biofrontera, Galderma, GlaxoSmithKline, Infectopharm, Janssen-Cilag, LEO Pharma, Meda, Neracare, Novartis, Riemser and is an advisory board member for Almirall, Biofrontera, Dr Pfleger, Galderma, GlaxoSmithKline, Janssen-Cilag, LEO Pharma, Meda, Neracare, Novartis, and Scibase. Brigitte Dréno has acted as investigator, consultant and/or speaker for Almirall, Avène, Bioderma, Fabre, Galderma, La RochePosay, L’Oreal, Novartis, and Sun Pharma. Linda Stein Gold has acted as an investigator/advisor and/or speaker for Almirall, Foamix, Galderma, Novartis, Ortho Derm, Sol-Gel, and Sun Pharma. Julie Harper has acted as a consultant for Almirall, BioPharmX, Cassiopea, Cutera, EPI, Foamix, Galderma, Ortho Derm, Sol-Gel, and Sun Pharma. Joo Yeon Ko has acted as a primary investigator for research (funded to institution) and/or received honoraria for unrestricted educational events from Amorepacific, Eli Lilly, and Galderma. Khaled Al Nuaimi has no relevant disclosures. Hazel H Oon has acted as a speaker, advisory board member and researcher for Galderma, a clinical investigator for Janssen, Novartis, and Pfizer and an advisory board member and speaker for AbbVie, Eli Lilly, and LEO Pharma. Murlidhar Rajagopalan has acted as a speaker and advisor for Galderma India, a consultant for Galderma and a speaker for Janssen, MSD, Novartis, Pfizer, Roche, and Sanofi. Marco Rocha has acted as an advisor, consultant, investigator and/or speaker and received grants/honoraria from Eucerin, FQMMelora, Galderma, Hypera, Johnson & Johnson, La Roche Posay, LEO Pharma, and Pierre-Fabre. Jo-Ann See has acted as an advisor, consultant, advisory board member and/or speaker for Allergan, Galderma, La Roche-Posay, LEO Pharma, L’Oreal, Mayne Pharma, and Viatris. Jonathan Weiss has acted as an investigator/advisor and/or speaker for Almirall, Dr Reddy’s, EPI Health, Foamix, Galderma, Novartis, and Ortho Derm. Jerry Tan has acted as an advisor, consultant, investigator and/or speaker and received grants/honoraria from Almirall, Bausch Health, Boots/Walgreens, Botanix, CeraVe, Cipher Pharmaceuticals, Cutera, Galderma, La Roche-Posay, Novan, Novartis, Pfizer, Promius, Sun Pharma, and Vichy.
(© 2023 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.)